lomustine and Anaplastic Oligodendroglioma studies

Research Excerpts

Excerpt	Relevance	Reference
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."	9.11	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
"Paclitaxel demonstrated modest efficacy with minimal toxicity in this pretreated cohort of adult patients with recurrent hemispheric oligodendrogliomas."	9.08	Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997)
" Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone."	8.31	T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023)
"Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted."	7.88	Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018)
" Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)."	7.73	Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005)
"To the authors' knowledge, there is a scarcity of accurate data regarding the feasibility of standard chemotherapy with procarbazine, lomustine, and vincristine (PCV) in a homogeneous series of patients with primary anaplastic oligodendroglioma (AO) and oligoastrocytoma (AOA) that was recurrent after surgery and standard radiotherapy."	7.72	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. ( Brandes, AA; Coria, B; Danieli, D; Ermani, M; Gardiman, M; Iuzzolino, P; Pasetto, LM; Talacchi, A; Tosoni, A; Vastola, F, 2004)
"The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms."	7.70	Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999)
"Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas."	7.69	[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997)
"Anaplastic oligodendroglioma are chemotherapy-sensitive tumors."	6.78	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013)
"Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas."	6.72	Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006)
"Temozolomide was in general well tolerated; the most frequent side-effects were hematological."	6.71	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003)
"NOA-18 aims at improving qualified overall survival (qOS) for adult patients with CNS WHO grade 2 and 3 oligodendrogliomas by randomizing between standard chemoradiation with up to six six-weekly cycles with PCV and six six-weekly cycles with lomustine and temozolomide (CETEG) (n = 182 patients per group accrued over 4 years) thereby delaying radiotherapy and adding the chemoradiotherapy concept at progression after initial radiation-free chemotherapy, allowing for effective salvage treatment and delaying potentially deleterious side effects."	5.51	Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. ( Baumann, L; Bendszus, M; Combs, S; Dormann, A; Haut, T; Kessler, T; Kieser, M; Koch, M; Limprecht, R; Merkle-Lock, J; Pertz, M; Platten, M; Sahm, F; Sander, A; Schlegel, U; Selkrig, N; Walter, S; Wick, A; Wick, W; Winkler, F, 2022)
"Patients with anaplastic oligodendrogliomas (n = 288) who were randomized (EORTC 26951) to radiotherapy (RT) alone or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy were analyzed."	5.20	Joint modeling of longitudinal health-related quality of life data and survival. ( Bottomley, A; Coens, C; Dirven, L; Ediebah, DE; Galindo-Garre, F; Reijneveld, JC; Ringash, J; Taphoorn, MJ; Uitdehaag, BM; van den Bent, MJ; Zikos, E, 2015)
"In patients with anaplastic oligodendroglioma or oligoastrocytoma tumors in whom temozolomide treatment has failed, osmotic blood-brain barrier disruption with IA carboplatin, IV etoposide phosphate, and IA melphalan (4 mg/m(2)/d for 2 days) shows acceptable toxicity and encouraging efficacy, especially in patients demonstrating 1p and/or 19q deletion."	5.14	Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. ( Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA, 2010)
" We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma."	5.14	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. ( Brandes, AA; Dinjens, WN; Dubbink, HJ; Frenay, M; Gorlia, T; Idbaih, A; Kros, JM; Lacombe, D; Marie, Y; Sanson, M; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Marion, R; Wesseling, P, 2010)
"We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue."	5.12	High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsay, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2006)
"Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival."	5.12	Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. ( Berkey, B; Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperierre, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L, 2006)
"Twenty-three patients with recurrent or progressive oligodendrogliomas or oligoastrocytomas after first-line PCV (procarbazine, lomustine, and vincristine) chemotherapy were enrolled in a single-institution Phase II study of second-line carboplatin chemotherapy."	5.11	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. ( Borgognone, M; Costanza, A; Laguzzi, E; Mutani, R; Nobile, M; Rudà, R; Soffietti, R, 2004)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."	5.11	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
" Here we report our experience with adjuvant postirradiation and preirradiation chemotherapy using procarbazine, lomustine, and vincristine (PCV) in 27 patients with WHO grade II or III oligodendroglioma or oligoastrocytoma."	5.09	A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. ( Bamberg, M; Dichgans, J; Grote, EH; Meyermann, R; Schabet, M; Streffer, J; Voigt, K; Weller, M, 2000)
"Paclitaxel demonstrated modest efficacy with minimal toxicity in this pretreated cohort of adult patients with recurrent hemispheric oligodendrogliomas."	5.08	Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997)
"To examine the rate and duration of response of anaplastic oligodendrogliomas to a dose-escalated combination chemotherapy regimen consisting of procarbazine, lomustine (CCNU), and vincristine (PCV) and to evaluate the side effects of this treatment."	5.07	Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. ( Buckner, J; Cairncross, G; Cascino, T; Dropcho, E; Fulton, D; Lee, D; Ludwin, S; Macdonald, D; Schold, C; Stewart, D, 1994)
"The association of radiotherapy and procarbazine, lomustine (CCNU), vincristine chemotherapy in low-grade oligodendrogliomas is definitely superior over radiotherapy alone, and yields median progression-free survival and overall survival values exceeding by far 10 years."	5.05	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? ( Rudà, R; Soffietti, R; Touat, M, 2020)
"Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion."	4.91	Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? ( Lassman, AB, 2015)
" Approximately two thirds of patients with the more aggressive form (anaplastic oligodendroglioma) have shown substantial response to first-line procarbazine/lomustine/vincristine (PCV) therapy."	4.81	Chemotherapy for the treatment of oligodendroglial tumors. ( Chinot, O, 2001)
" Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone."	4.31	T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023)
"Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy."	4.02	PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. ( Egensperger, R; Karschnia, P; Katzendobler, S; Lietke, S; Suchorska, B; Thon, N; Tonn, JC; Weller, J; Weller, M, 2021)
"Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted."	3.88	Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018)
"While procarbazine with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit."	3.81	PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. ( De Groot, J; Liu, D; Shonka, N; Smith, L; Webre, C, 2015)
" This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma."	3.79	How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. ( van den Bent, MJ, 2013)
"The long-term follow-up results from the EORTC-26951 trial showed that the addition of procarbazine, CCNU, and vincristine (PCV) after radiotherapy increases survival in anaplastic oligodendrogliomas/oligoastrocytomas (AOD/AOA)."	3.79	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Tijssen, C; van den Bent, MJ; Wesseling, P, 2013)
" Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)."	3.73	Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005)
"We report the long-term follow-up, 71 months, of seven patients treated by procarbazine, lomustine and vincristine (PCV) therapy for a symptomatic low-grade oligodendrogliomatous tumor."	3.73	[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. ( Cartalat-Carel, S; Catenoix, H; Chapuis, F; Honnorat, J; Nighoghossian, N; Trouillas, P, 2006)
"To the authors' knowledge, there is a scarcity of accurate data regarding the feasibility of standard chemotherapy with procarbazine, lomustine, and vincristine (PCV) in a homogeneous series of patients with primary anaplastic oligodendroglioma (AO) and oligoastrocytoma (AOA) that was recurrent after surgery and standard radiotherapy."	3.72	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. ( Brandes, AA; Coria, B; Danieli, D; Ermani, M; Gardiman, M; Iuzzolino, P; Pasetto, LM; Talacchi, A; Tosoni, A; Vastola, F, 2004)
"The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms."	3.70	Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999)
"We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma."	3.69	Low-grade oligodendroglioma responds to chemotherapy. ( DeAngelis, LM; Krol, GS; Mason, WP, 1996)
"Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas."	3.69	[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997)
"Anaplastic oligodendroglioma are chemotherapy-sensitive tumors."	2.78	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013)
"The prognosis of patients with anaplastic oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable."	2.78	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai ( Bernsen, HJ; Brandes, AA; Delattre, JY; Frénay, M; Gorlia, T; Kouwenhoven, MC; Kros, JM; Lacombe, D; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2013)
"RT alone for anaplastic oligodendroglioma."	2.75	Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. ( Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperriere, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L; Wang, M, 2010)
"AOA tumors with necrosis are to be considered WHO grade IV tumors (GBM)."	2.74	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. ( Allgeier, A; Brandes, AA; Bromberg, JE; Gorlia, T; Grisold, W; Ibdaih, A; Kouwenhoven, MC; Kros, JM; Lacombe, D; Mirimanoff, R; Mokhtari, K; Sipos, L; Teepen, JL; van den Bent, MJ; van Duinen, SG; Vandenbos, F; Vecht, CJ; Wesseling, P, 2009)
"Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed."	2.73	Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. ( Bourg, V; Chanalet, S; Fauchon, F; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Paquis, P; Ramaioli, A; Vandenbos, F, 2007)
"Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy."	2.73	Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. ( Allgeier, A; Bernsen, HJ; Bottomley, A; Brandes, AA; Coens, C; Delattre, JY; Frénay, M; Lacombe, D; Mauer, ME; Sillevis Smitt, PA; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2007)
"Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas."	2.72	Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006)
"Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity."	2.71	Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004)
"Anaplastic oligodendroglioma is a chemosensitive glial neoplasm."	2.71	High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsey, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2003)
"Temozolomide was in general well tolerated; the most frequent side-effects were hematological."	2.71	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003)
"Histologically, 69 had anaplastic astrocytoma; 14, anaplastic oligoastrocytoma; and 7, anaplastic oligodendroglioma."	2.70	Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. ( Bruner, J; Chang, E; Gleason, MJ; Hess, KR; Ictech, SA; Kyritsis, A; Leeds, N; Levin, VA; Maor, MH; Meyers, CA; Yung, WK, 2002)
"The incidence of oligodendroglioma is increasing, most likely due to its improved recognition."	2.42	Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. ( Engelhard, HH; Mundt, A; Stelea, A, 2003)
"Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted."	2.41	PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. ( Diabira, S; Gamelin, E; Jadaud, E; Menei, P; Rousselet, MC; Soulier, P, 2001)
"Oligodendrogliomas were clearly defined as tumors with IDH mutations and 1p/19q codeletion by the World Health Organization(WHO)in 2016."	1.91	[Oligodendroglioma, IDH Mutation and 1p/19q Codeletion]. ( Matsutani, T, 2023)
"Temozolomide-based treatment was administered to 64 of 68 (94."	1.72	Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. ( Aichholzer, M; Berghoff, AS; Dieckmann, K; Furtner, J; Goldberger, S; Hatziioannou, T; Heller, G; Leibetseder, A; Mair, MJ; Pichler, J; Preusser, M; Puhr, R; Tomasich, E; von Oertzen, T; Weis, S; Widhalm, G; Wöhrer, A, 2022)
"Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas."	1.32	Long-term outcome of oligodendrogliomas. ( Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F, 2004)
"Oligodendroglioma is a rare central nervous system tumor which may occur in pure or mixed histology."	1.30	Radiation and chemotherapy improve outcome in oligodendroglioma. ( Allison, RR; Barry, T; Schulsinger, A; Shin, KH; Vongtama, V, 1997)
"Malignant oligodendrogliomas have been shown to be responsive to chemotherapy."	1.28	The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. ( Glass, J; Gruber, ML; Hochberg, FH; Louis, DN; Rattner, B; Smith, D, 1992)
"Malignant oligodendroglioma is a uniquely chemosensitive glial tumor."	1.27	Successful chemotherapy for recurrent malignant oligodendroglioma. ( Cairncross, JG; Macdonald, DR, 1988)

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (6.06)	18.7374
1990's	18 (18.18)	18.2507
2000's	43 (43.43)	29.6817
2010's	26 (26.26)	24.3611
2020's	6 (6.06)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521]	Phase 3	406 participants (Anticipated)	Interventional	2021-04-07	Recruiting
A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375]	Phase 2/Phase 3	370 participants (Actual)	Interventional	1998-10-31	Completed
PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840]	Phase 3	350 participants (Anticipated)	Interventional	1996-08-31	Completed
Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas[NCT00002569]	Phase 3	299 participants (Actual)	Interventional	1994-07-31	Completed
PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806]	Phase 2	43 participants (Actual)	Interventional	1996-07-31	Completed
Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304]	Phase 2	29 participants (Anticipated)	Interventional	1998-04-30	Completed
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas[NCT01445119]	Phase 1	58 participants (Actual)	Interventional	2007-01-31	Completed
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071]	Phase 1	9 participants (Actual)	Interventional	2009-09-22	Completed
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative[NCT00031538]		674 participants (Actual)	Observational	2002-03-01	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? Current opinion in neurology, 2020, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen	2020
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? CNS oncology, 2015, Volume: 4, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol	2015
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon. International journal of radiation oncology, biology, physics, 2003, May-01, Volume: 56, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries	2003
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surgical neurology, 2003, Volume: 60, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine	2003
Oligodendroglioma. Current treatment options in oncology, 2003, Volume: 4, Issue:6 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv	2003
[The molecular genetics of oligodendroglioma]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2004, Volume: 33, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos	2004
Anaplastic oligodendroglioma and oligoastrocytoma. Neurologic clinics, 2007, Volume: 25, Issue:4 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai	2007
[Clinical significance of mustoforan in management of malignant glioma]. Voprosy onkologii, 2007, Volume: 53, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr	2007
Treatment of neuroectodermal brain tumors. Annals of neurology, 1982, Volume: 12, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms;	1982
Aggressive oligodendroglioma: a chemosensitive tumor. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1994, Volume: 135 Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad	1994
Chemotherapy of low-grade gliomas. Seminars in radiation oncology, 2001, Volume: 11, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi	2001
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. Seminars in radiation oncology, 2001, Volume: 11, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G	2001
Chemotherapy for the treatment of oligodendroglial tumors. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous S	2001
PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. Journal of neuro-oncology, 2001, Volume: 55, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M	2001
[Chemo-radiotherapy for malignant brain tumors]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System	2002
Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery, 1992, Volume: 31, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Crani	1992

Article	Year
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. BMC cancer, 2022, Jun-13, Volume: 22, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm	2022
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:16 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tu	2013
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chi-Square Distr	2014
Joint modeling of longitudinal health-related quality of life data and survival. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Hu	2015
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. The New England journal of medicine, 2016, Apr-07, Volume: 374, Issue:14 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali	2016
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-oncology, 2009, Volume: 11, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cell Proliferation; Ch	2009
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation oncology, biology, physics, 2010, Jul-01, Volume: 77, Issue:3 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cognition; Combined Mo	2010
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant	2009
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery, 2010, Volume: 66, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl	2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M	2010
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of neuro-oncology, 2011, Volume: 103, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chr	2011
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. Cancer, 2011, Jul-01, Volume: 117, Issue:13 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined	2011
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Fre	2013
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosomes, Hum	2013
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber	2003
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop	2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. Journal of neuro-oncology, 2003, Volume: 65, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin	2003
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer, 2004, Feb-15, Volume: 100, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;	2004
Initial chemotherapy in gliomatosis cerebri. Neurology, 2004, Jul-27, Volume: 63, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin	2004
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology, 2004, Sep-14, Volume: 63, Issue:5 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom	2004
Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience. Neurology, 2006, Jan-24, Volume: 66, Issue:2 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;	2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro-oncology, 2006, Volume: 8, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brai	2006
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant	2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant	2006
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. European journal of neurology, 2007, Volume: 14, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Disease	2007
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-20, Volume: 25, Issue:36 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo	2007
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. Journal of neuro-oncology, 2008, Volume: 89, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Busulfan; Combi	2008
Treatment of neuroectodermal brain tumors. Annals of neurology, 1982, Volume: 12, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms;	1982
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Canada; Ce	1994
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:12 Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols;	1997
Combined treatment modality for anaplastic oligodendroglioma: a phase II study. Journal of neuro-oncology, 1999, Volume: 43, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; D	1999
A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. Journal of neurology, 2000, Volume: 247, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin	2000
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. International journal of radiation oncology, biology, physics, 2002, May-01, Volume: 53, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm	2002
Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clinical neurology and neurosurgery, 1985, Volume: 87, Issue:3 Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Combine	1985

Article	Year
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-14, Volume: 28, Issue:20 Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer	2022
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. European journal of neurology, 2023, Volume: 30, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Magnetic Resonan	2023
[Oligodendroglioma, IDH Mutation and 1p/19q Codeletion]. No shinkei geka. Neurological surgery, 2023, Volume: 51, Issue:5 Topics: Cognition; Glioma; Humans; Lomustine; Mutation; Oligodendroglioma	2023
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. Journal of neuro-oncology, 2021, Volume: 153, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging	2021
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. Revista de neurologia, 2018, Oct-16, Volume: 67, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai	2018
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. Journal of neuro-oncology, 2013, Volume: 113, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase III as Topic	2013
How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2013 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Deletion; Chromosomes, H	2013
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current treatment options in oncology, 2013, Volume: 14, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Female;	2013
MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-01, Volume: 19, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cluster Analysis; CpG Islands; DNA Methy	2013
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. Journal of neuro-oncology, 2015, Volume: 121, Issue:2 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Drug Therapy, Combination; Femal	2015
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;	2015
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj	2015
Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone. Journal of neurosurgery, 2015, Volume: 123, Issue:5 Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy	2015
PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. Anticancer research, 2015, Volume: 35, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astr	2015
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva	2015
Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. BMC neurology, 2009, Jul-16, Volume: 9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Chi	2009
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology, 2011, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr	2011
Long-term survival in a dog with anaplastic oligodendroglioma treated with radiation therapy and CCNU. The Journal of veterinary medical science, 2012, Volume: 74, Issue:11 Topics: Animals; Dog Diseases; Dogs; Fatal Outcome; Immunohistochemistry; Lomustine; Magnetic Resonance Imag	2012
Chemotherapy and radiotherapy combination extends survival for patients with oligodendroglial tumors. Cancer, 2012, Sep-15, Volume: 118, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Chemoradiothera	2012
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. Journal of neurology, 2002, Volume: 249, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female	2002
Glioma treatment, radionecrosis, and growth factors. In regard to Levin et al., IJROBP 2002;53:58-66. International journal of radiation oncology, biology, physics, 2003, Mar-01, Volume: 55, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Diseases; Brain Neoplasms; Carbop	2003
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer, 2003, Mar-01, Volume: 97, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes	2003
Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology, 2003, Mar-11, Volume: 60, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat	2003
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology, 2003, Aug-12, Volume: 61, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair	2003
Long-term outcome of oligodendrogliomas. Neurology, 2004, May-25, Volume: 62, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci	2004
Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer, 2004, Nov-01, Volume: 101, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Combined Modality Therapy;	2004
Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 2005, Feb-15, Volume: 103, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo	2005
Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. Journal of neuro-oncology, 2005, Volume: 71, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomust	2005
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology, 2006, Jun-13, Volume: 66, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Control Studies;	2006
Anaplastic oligodendroglial tumors: a tale of two trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr	2006
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10 Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes,	2006
[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. Revue neurologique, 2006, Volume: 162, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo	2006
Response and control: lessons from oligodendroglioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Oligodendrogliom	1995
Brain tumor chemotherapy trials: slow start, but quickly gaining. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Humans; L	1994
Low-grade oligodendroglioma responds to chemotherapy. Neurology, 1996, Volume: 46, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M	1996
Radiation and chemotherapy improve outcome in oligodendroglioma. International journal of radiation oncology, biology, physics, 1997, Jan-15, Volume: 37, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine	1997
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. Bulletin du cancer, 1997, Volume: 84, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl	1997
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. Journal of neuro-oncology, 1998, Volume: 38, Issue:1 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop	1998
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology, 1998, Volume: 51, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Co	1998
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anti-cancer drugs, 1999, Volume: 10, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R	1999
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology, 1999, Sep-22, Volume: 53, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Fem	1999
Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment. British journal of neurosurgery, 1998, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm	1998
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-oncology, 2000, Volume: 2, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta	2000
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases. Acta neurologica, 1979, Volume: 1, Issue:1 Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma	1979
Desmosterol: a biochemical marker of glioma growth. Surgical neurology, 1977, Volume: 8, Issue:6 Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis,	1977
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors. Pharmacological research communications, 1976, Volume: 8, Issue:2 Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I	1976
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. Journal of neurosurgery, 1992, Volume: 76, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Admi	1992
Chemotherapy for oligodendroglioma. Progress report. Archives of neurology, 1991, Volume: 48, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Recurre	1991
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Annals of neurology, 1990, Volume: 27, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M	1990
Successful chemotherapy for recurrent malignant oligodendroglioma. Annals of neurology, 1988, Volume: 23, Issue:4 Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans	1988

lomustine and Anaplastic Oligodendroglioma

Research Excerpts

Research

Studies (99)

Authors

Clinical Trials (9)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Wick, A	1
Sander, A	1
Koch, M	1
Bendszus, M	1
Combs, S	1
Haut, T	1
Dormann, A	1
Walter, S	1
Pertz, M	1
Merkle-Lock, J	1
Selkrig, N	1
Limprecht, R	1
Baumann, L	1
Kieser, M	1
Sahm, F	1
Schlegel, U	2
Winkler, F	1
Platten, M	1
Wick, W	2
Kessler, T	1
Mair, MJ	1
Leibetseder, A	1
Heller, G	1
Puhr, R	1
Tomasich, E	1
Goldberger, S	1
Hatziioannou, T	1
Wöhrer, A	1
Widhalm, G	1
Dieckmann, K	1
Aichholzer, M	1
Weis, S	1
von Oertzen, T	1
Furtner, J	1
Pichler, J	1
Preusser, M	1
Berghoff, AS	1
Esparragosa Vazquez, I	1
Ndiaye, M	1
Di Stefano, AL	1
Younan, N	1
Larrieu-Ciron, D	1
Seyve, A	1
Picart, T	1
Meyronet, D	1
Boutet, C	1
Vassal, F	1
Carpentier, C	2
Figarella-Branger, D	1
Dehais, C	1
Forest, F	1
Rivoirard, R	1
Ducray, F	3
Matsutani, T	1
Rudà, R	2
Touat, M	1
Soffietti, R	2
Weller, J	1
Katzendobler, S	1
Karschnia, P	1
Lietke, S	1
Egensperger, R	1
Thon, N	1
Weller, M	3
Suchorska, B	1
Tonn, JC	1
Gonzalez-Aguilar, A	1
Reyes-Moreno, I	1
Peiro-Osuna, RP	1
Hernandez-Hernandez, A	1
Gutierrez-Aceves, A	1
Santos-Zambrano, J	1
Guerrero-Juarez, V	1
Lopez-Martinez, M	1
Castro-Martinez, E	1
Villano, JL	1
Wen, PY	3
Lee, EQ	1
Nayak, L	1
Reardon, DA	1
Rosenfeld, MR	1
van den Bent, MJ	17
Gorlia, T	9
Delattre, JY	5
Brandes, AA	9
Kros, JM	15
Taphoorn, MJ	10
Kouwenhoven, MC	3
Bernsen, HJ	4
Frénay, M	9
Tijssen, CC	6
Lacombe, D	7
Roth, P	1
Erdem-Eraslan, L	1
Idbaih, A	4
de Rooi, J	1
Eilers, PH	1
Spliet, WG	1
den Dunnen, WF	1
Tijssen, C	1
Wesseling, P	4
Sillevis Smitt, PA	4
French, PJ	2
Cairncross, JG	13
Wang, M	3
Jenkins, RB	2
Shaw, EG	3
Giannini, C	1
Brachman, DG	1
Buckner, JC	3
Fink, KL	1
Souhami, L	4
Laperriere, NJ	1
Huse, JT	1
Mehta, MP	2
Curran, WJ	2
Ediebah, DE	1
Galindo-Garre, F	1
Uitdehaag, BM	2
Ringash, J	1
Reijneveld, JC	1
Dirven, L	1
Zikos, E	1
Coens, C	2
Bottomley, A	2
Taal, W	1
van der Rijt, CC	2
Dinjens, WN	4
Wertenbroek, AA	1
Bromberg, JE	2
van Heuvel, I	3
Levin, VA	2
Rinne, ML	1
Kaloshi, G	1
Roci, E	1
Rroji, A	1
Petrela, M	1
Webre, C	1
Shonka, N	1
Smith, L	1
Liu, D	1
De Groot, J	1
Lassman, AB	2
Pugh, SL	1
Chakravarti, A	1
Gilbert, MR	2
Barger, GR	1
Coons, S	1
Ricci, P	1
Bullard, D	1
Brown, PD	2
Stelzer, K	1
Brachman, D	4
Suh, JH	1
Schultz, CJ	1
Bahary, JP	1
Fisher, BJ	2
Kim, H	1
Murtha, AD	1
Bell, EH	1
Won, M	1
Ibdaih, A	2
Mokhtari, K	4
van Duinen, SG	1
Teepen, JL	1
Vandenbos, F	3
Grisold, W	3
Sipos, L	3
Mirimanoff, R	1
Vecht, CJ	4
Allgeier, A	5
Vesper, J	1
Graf, E	1
Wille, C	1
Tilgner, J	1
Trippel, M	1
Nikkhah, G	1
Ostertag, C	1
Cairncross, G	5
Shaw, E	3
Jenkins, R	4
Scheithauer, B	2
Buckner, J	4
Fink, K	3
Laperriere, N	2
Mehta, M	3
Curran, W	3
Dubbink, HJ	2
Sanson, M	6
van der Lee-Haarloo, CR	1
Hegi, M	1
Jeuken, JW	1
Guillaume, DJ	1
Doolittle, ND	1
Gahramanov, S	1
Hedrick, NA	1
Delashaw, JB	1
Neuwelt, EA	1
Marie, Y	1
van Marion, R	1
Dalmasso, C	1
Kouwenhoven, M	1
Jeuken, J	1
French, P	1
Teepen, J	1
Broët, P	1
Delattre, O	1
van den Bent, M	2
Hoang-Xuan, K	4
Taphoorn, M	1
Iwamoto, FM	1
Cloughesy, TF	1
Aldape, KD	1
Rivera, AL	1
Eichler, AF	1
Louis, DN	3
Paleologos, NA	2
Ashby, LS	1
Roldán, GB	1
Ligon, KL	1
Schiff, D	2
Robins, HI	1
Rocque, BG	1
Chamberlain, MC	2
Mason, WP	2
Weaver, SA	1
Green, RM	1
Kamar, FG	1
Abrey, LE	4
DeAngelis, LM	4
Jhanwar, SC	1
Rosenblum, MK	1
Panageas, KS	1
Hasegawa, D	1
Uchida, K	1
Kuwabara, T	1
Mizoguchi, S	1
Yayoshi, N	1
Fujita, M	1
Printz, C	1
Enting, RH	3
Zander, T	1
Nettekoven, W	1
Kraus, JA	1
Pels, H	1
Ko, YD	1
Vetter, H	1
Klockgether, T	1
Gesme, D	1
O'Fallon, JR	1
Hammack, JE	1
Stafford, S	1
Hawkins, R	1
Scheithauer, BW	1
Erickson, BJ	1
Levitt, R	1
Nieder, C	1
Looijenga, LH	2
Langenberg, K	1
Dinjens, W	1
Graveland, W	1
Uytdewilligen, L	1
Vos, MJ	1
Barkhof, F	1
Heimans, JJ	3
Baayen, HC	1
Boogerd, W	3
Castelijns, JA	1
Elkhuizen, PH	1
Postma, TJ	2
Chinot, O	3
Bravo Marques, J	1
De Beule, N	1
Baron, B	1
Sunyach, MP	1
Pommier, P	1
Martel Lafay, I	1
Guyotat, J	1
Ginestet, G	1
Jouanneau, E	1
Jouvet, A	3
Sindou, M	3
Bret, P	2
Carrie, C	1
Frappaz, D	1
Engelhard, HH	1
Stelea, A	1
Mundt, A	1
Ellis, TL	1
Stieber, VW	1
Austin, RC	1
Childs, BH	2
Paleologos, N	4
Kaminer, L	3
Rosenfeld, S	3
Salzman, D	3
Finlay, JL	2
Gardner, S	2
Peterson, K	3
Hu, W	3
Swinnen, L	3
Bayer, R	3
Forsyth, P	4
Stewart, D	5
Smith, AM	2
Macdonald, DR	7
Weaver, S	2
Ramsey, DA	1
Nimer, SD	2
Nobile, M	1
Borgognone, M	1
Costanza, A	1
Laguzzi, E	1
Mutani, R	1
Lebrun, C	2
Fontaine, D	2
Ramaioli, A	2
Chanalet, S	2
Lonjon, M	2
Michiels, JF	1
Bourg, V	2
Paquis, P	2
Chatel, M	1
Cartalat-Carel, S	2
Taillibert, S	1
Napolitano, M	1
Djafari, L	1
Cougnard, J	1
Gervais, H	1
Laigle, F	1
Carpentier, A	1
Taillandier, L	1
Duffau, H	1
Honnorat, J	2
Triebels, VH	1
Menten, J	1
Tosoni, A	2
Stege, EB	1
Vastola, F	1
Pasetto, LM	1
Coria, B	1
Danieli, D	1
Iuzzolino, P	1
Gardiman, M	1
Talacchi, A	1
Ermani, M	1
Teng, LH	1
Gui, QP	1
Xuan, Q	1
Lu, DH	1
Stege, EM	1
de Bruin, HG	1
van der Rijt, CD	1
Smitt, PA	1
Tang, BN	1
Sadeghi, N	1
Branle, F	1
De Witte, O	1
Wikler, D	1
Goldman, S	1
Ty, AU	1
See, SJ	1
Rao, JP	1
Khoo, JB	1
Wong, MC	1
Ramsay, DA	2
Walker, C	2
Haylock, B	2
Husband, D	2
Joyce, KA	2
Fildes, D	2
Jenkinson, MD	2
Smith, T	2
Broome, J	2
du Plessis, DG	2
Warnke, PC	2
Lang, FF	1
Berkey, B	1
Laperierre, N	1
Carpentier, AF	1
Haaxma-Reiche, H	1
van Kouwenhoven, MC	1
Kopitzki, K	1
Prosser, J	1
Vinjamuri, S	1
Catenoix, H	1
Chapuis, F	1
Nighoghossian, N	1
Trouillas, P	1
Fauchon, F	1
Mauer, ME	1
Kobiakov, GL	1
Mohile, NA	1
Raizer, JJ	1
Kewalramani, T	1
Shapiro, WR	1
Eisenhauer, EA	1
Fine, HA	1
Macdonald, D	2
Ludwin, S	1
Lee, D	1
Cascino, T	1
Fulton, D	1
Dropcho, E	1
Schold, C	1
Krol, GS	1
Allison, RR	1
Schulsinger, A	1
Vongtama, V	1
Barry, T	1
Shin, KH	1
Kormanik, PA	1
Bouffet, E	2
Mornex, F	1
Thiesse, P	2
Mertens, P	1
Helfre, S	1
van Groeningen, CJ	2
Witjes, RJ	1
Weerts, JG	1
Kralendonk, JH	1
Pronk, LC	1
Krouwer, HG	1
Zonnenberg, BA	1
Twijnstra, A	1
Punt, CJ	1
Sankar, A	1
Thomas, DG	1
Darling, JL	1
Vick, NA	1
Jeremic, B	1
Shibamoto, Y	1
Gruijicic, D	1
Milicic, B	1
Stojanovic, M	1
Nikolic, N	1
Dagovic, A	1
Aleksandrovic, J	1
Streffer, J	1
Schabet, M	1
Bamberg, M	1
Grote, EH	1
Meyermann, R	1
Voigt, K	1
Dichgans, J	1
Lesser, GJ	1
Bauman, GS	1
Ramsay, D	1
Smith, A	1
Diabira, S	1
Rousselet, MC	1
Gamelin, E	1
Soulier, P	1
Jadaud, E	1
Menei, P	1
Yung, WK	1
Bruner, J	1
Kyritsis, A	1
Leeds, N	1
Gleason, MJ	1
Hess, KR	1
Meyers, CA	1
Ictech, SA	1
Chang, E	1
Maor, MH	1
Kochi, M	1
Ushio, Y	1
Paoletti, P	3
Baldini, M	1
Knerich, R	1
Princi, L	1
Fumagalli, R	2
Weiss, JF	1
Pezzotta, S	2
Racca, AR	1
Glass, J	1
Hochberg, FH	1
Gruber, ML	1
Smith, D	1
Rattner, B	1
Gaspar, LE	1
Müller, H	1
Brock, M	1
Ernst, H	1